Inclusion Criteria:  18 years old ≤ age ≤ 80 years old;  Diagnosed as thoracoabdominal aortic aneurysm (based on modified Crawford classification and 2019 European Guidelines for the Treatment of Aortic aneurysm) and should meet at least one of the following conditions;  Maximum diameter of thoracoabdominal aortic aneurysm>50mm; The diameter has increased by more than 5mm in recent 6 months or the by more than 10mm in recent 1 year;  anatomical criteria  The proximal anchoring region (aorta or implanted graft) was 17~36 mm in diameter and ≥25 mm in length; Distal anchoring region (aorta or implanted graft): If the distal anchoring region is in the iliac artery, the anchoring region has a diameter range of 7~25 mm and a length of ≥15 mm; If the distal anchoring area is in the abdominal aorta, the diameter of the anchoring area ranges from 12~36mm and the length≥ 20mm; The diameter of the vessel anchoring area of the visceral branch ranges from 6~13 mm and the length ≥15 mm; The diameter of renal artery anchoring area ranges from 4.5~9mm, and the length ≥15 mm; Appropriate iliac, femoral and upper limb artery access; Patients who can understand the purpose of the trial, voluntarily participate and sign the informed consent, and are willing to complete the follow-up according to the requirements of the protocol;  Exclusion Criteria:  Hemodynamically unstable patients with ruptured thoracoabdominal aortic aneurysms; Thoracoabdominal aortic dissection; Mycotic or infectious thoracoabdominal aortic aneurysm; Patients whose systemic or local infection may increase the risk of intravascular graft infection; Superior mesenteric, celiac, or renal artery occlusion; Requiring simultaneous coverage and embolization of bilateral internal iliac arteries; Severe stenosis, calcification, or mural thrombus in the anchoring area of the stent tend to have difficulty in attachment of the stent-graft or affect the patency of the stent; A history of acute coronary syndrome within 6 months; Acute coronary syndrome is defined as an acute ischemic syndrome of the heart resulting from the rupture or erosion of unstable intracoronary atherosclerotic plaques followed by fresh thrombosis, including ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, and unstable angina pectoris. Transient ischemic attack (TIA) or ischemic/haemorrhagic stroke within 3 months; Preoperative liver renal function abnormalities (ALT or AST ≥ 5 times the upper limit of normal value), or serum creatinine ≥ 150 μmol/L; Severe pulmonary insufficiency who cannot tolerate general anaesthesia; Severe coagulation dysfunction; Undergone major surgical or interventionic surgery within 30 days before surgery; A history of allergy to contrast agents, anticoagulants, antiplatelet drugs, stents, and conveyor materials (nitinol, polyester, PTFE, nylon); Connective tissue diseases such as systemic lupus erythematosus, Marfan's syndrome, Adam's syndrome, or Behcet's disease; Patients with arteritis; Serious vital organ dysfunction or other serious disease; Planning pregnancy, pregnancy, or breastfeeding; Patients who participated in other clinical trials and was not discontinued or withdrawn within the first 3 months of the screening period of this trial. Life expectancy less than 1 year; Patients who, in the judgment of the investigator, are not eligible for endotherapy.